• Hemogenyx Pharmaceuticals PLC (PNK:HOPHF) will execute a reverse stock split on December 13, 2024, converting 400 shares into 1 share.
• This move restructures the company’s capital by subdividing and reclassifying existing shares to streamline its share structure.
• HOPHF is currently valued at $0.0031, holding a market capitalization of approximately $19.9 million.

On December 13, 2024, Hemogenyx Pharmaceuticals will proceed with a reverse stock split, where 400 existing shares will be combined into 1 share. The restructuring aims to enhance the capital structure of Hemogenyx Pharmaceuticals PLC, a developer of advanced therapies for blood diseases, listed under the symbol HEMO on the London Stock Exchange.

This strategic move follows the approval of resolutions during an Extraordinary General Meeting held on December 9, 2024, allowing the company to reorganize its share structure by classifying and subdividing its 1.4 billion ordinary shares on a 1:2 basis. Each ordinary share will now comprise one new share and one deferred share.

The stock symbol HOPHF presently trades at $0.0031, showing a daily low of $0.0031 and a high of $0.04. In the past year, the stock saw a maximum price of $0.04 and a minimum price of $0.0031. The total market capitalization stands around $19.9 million, while today’s trading volume reached 25,000 shares.